<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01645202</url>
  </required_header>
  <id_info>
    <org_study_id>SK 107 -- 012/12 (II)</org_study_id>
    <nct_id>NCT01645202</nct_id>
  </id_info>
  <brief_title>A Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: The CHOICE Trial</brief_title>
  <acronym>CHOICE</acronym>
  <official_title>A Randomized Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic CoreValve Versus Edwards SAPIEN XT (The CHOICE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled multicenter study comparing the acute hemodynamic performance of the
      Edwards Sapien XT and the Medtronic CoreValve transcatheter heart valves in high risk
      patients with severe symptomatic aortic stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: randomized open-label multicenter

      Primary endpoint:

      'Device success' as recently defined by VARC which is a 'technical' composite endpoint
      including:

        1. Successful vascular access, delivery and deployment of the device and successful
           retrieval of the delivery system,

        2. Correct position of the device in the proper anatomical location,

        3. Intended performance of the prosthetic heart valve (aortic valve area &gt; 1.2 cm2 and mean
           aortic valve gradient &lt; 20 mmHg or peak velocity &lt; 3 m/s, without moderate or severe
           prosthetic valve AR) and

        4. Only one valve implanted in the proper anatomical location.

      Secondary endpoints:

        -  30-day-combined safety endpoint which is a combined endpoint defined by VARC as:

             1. All cause mortality,

             2. Major stroke,

             3. Life threatening (or disabling) bleeding,

             4. Acute kidney injury-Stage 3 (including renal replacement therapy),

             5. Periprocedural myocardial infarction,

             6. Major vascular complications and

             7. Repeat procedure for valve-related dysfunction (surgical or interventional
                therapy). *

        -  Combined efficacy endpoint at 1 year which is a composite endpoint defined by VARC as:

             1. All cause mortality between 30 days and one year,

             2. Failure of current therapy for aortic stenosis, requiring hospitalization for
                symptoms of valve-related or cardiac decompensation and

             3. Prosthetic heart valve dysfunction (aortic valve area &lt; 1.2 cm2 and mean aortic
                valve gradient &gt; 20 mmHg or peak velocity &gt; 3 m/s or moderate or severe prosthetic
                valve AR). *

        -  Cardiovascular mortality as defined by VARC at 1 month, 6 and 12 months. *

        -  Major adverse cardiovascular and cerebrovascular events (MACCE): myocardial infarction,
           cardiac or vascular surgery and stroke at 30 days, 6 &amp; 12 months.

        -  Rehospitalization for heart failure at 12 months

        -  Quality of life (assessed with the Euro5Qual-questionnaire) at 12 months

        -  NYHA-class improvement at 30 days, 6 and 12 months

        -  Vascular complication as defined by VARC at 30 days.

        -  Post-procedural pacemaker implantation at 1 month

        -  Major or minor Bleeding at 30 days as defined be VARC.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>'Device success' as recently defined by the Valve Academic Research Consortium</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Device success is a 'technical' composite endpoint including successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system, correct position of the device in the proper anatomical location, intended performance of the prosthetic heart valve (aortic valve area &gt; 1.2 cm2 and mean aortic valve gradient &lt; 20 mmHg or peak velocity &lt; 3 m/s, without moderate or severe prosthetic valve AR) and only one valve implanted in the proper anatomical location.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VARC-defined combined safety endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Combined endpoint defined by VARC as: 1) All cause mortality, 2) Major stroke, 3) Life threatening (or disabling) bleeding, 4) Acute kidney injury-Stage 3 (including renal replacement therapy), 5) Periprocedural myocardial infarction, 6) Major vascular complications and 7) Repeat procedure for valve-related dysfunction (surgical or interventional therapy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VARC-defined combined efficacy endpoint</measure>
    <time_frame>1 year</time_frame>
    <description>A composite endpoint defined by VARC as: 1) All cause mortality between 30 days and one year, 2) Failure of current therapy for aortic stenosis, requiring hospitalization for symptoms of valve-related or cardiac decompensation and 3) Prosthetic heart valve dysfunction (aortic valve area &lt; 1.2 cm2 and mean aortic valve gradient &gt; 20 mmHg or peak velocity &gt; 3 m/s or moderate or severe prosthetic valve AR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVI with Edwards Sapien XT valve</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVI with Medtronic CoreValve</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation (TAVI)</intervention_name>
    <description>Comparison of different types of valves</description>
    <arm_group_label>TAVI with Edwards Sapien XT valve</arm_group_label>
    <arm_group_label>TAVI with Medtronic CoreValve</arm_group_label>
    <other_name>Transcatheter Aortic Valve Replacement (TAVR)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe aortic valve stenosis defined as aortic valve area (AVA) ≤ 1cm2 or 0.6 cm2/m2

          2. Presence of clinical symptoms defined as New York Heart Association (NYHA) functional
             class ≥ 2

          3. Age &gt; 75 years and/or Logistic EuroSCORE ≥ 20% and/or STS risk score ≥ 10% and/or
             contraindication to conventional surgical aortic valve replacement (porcelain aorta,
             previous chest radiation, chest deformation)

          4. Native aortic valve annulus measuring 20-25 mm

          5. Patients must be suitable for a transfemoral vascular access

          6. The patient signing a written informed consent prior to intervention

        Exclusion Criteria:

          1. Life expectancy &lt; 12 months due to co-morbid conditions

          2. Native aortic valve annulus &lt; 20 mm and &gt; 25 mm (this could be amended if further
             valve sizes for the transfemoral approach become available for both prostheses during
             the study period)

          3. Pre-existing aortic bioprosthesis

          4. Cardiogenic shock or hemodynamic instability

          5. History of, or active endocarditis

          6. Contraindications for a transfemoral access

          7. Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months.

          8. Hypersensitivity or contraindication to aspirin, heparin or clopidogrel

          9. Active infection requiring antibiotic treatment

         10. An elective surgical procedure is planned that would necessitate interruption of
             thienopyridines during the first 3 months post-enrolment

         11. Patients actively participating in another drug or device investigational study and
             have not yet completed the primary endpoint follow-up period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Abdel-Wahab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum, Segeberger Kliniken, Bad Segeberg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gert Richardt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herzzentrum, Segeberger Kliniken, Bad Segeberg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Segeberger Kliniken GmbH / Herzzentrum</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig-Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22.</citation>
    <PMID>20961243</PMID>
  </reference>
  <reference>
    <citation>Grube E, Schuler G, Buellesfeld L, Gerckens U, Linke A, Wenaweser P, Sauren B, Mohr FW, Walther T, Zickmann B, Iversen S, Felderhoff T, Cartier R, Bonan R. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol. 2007 Jul 3;50(1):69-76. Epub 2007 Jun 6.</citation>
    <PMID>17601548</PMID>
  </reference>
  <reference>
    <citation>Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD, Young CP, Thomas M, Kovac J, Spyt T, MacCarthy PA, Wendler O, Hildick-Smith D, Davies SW, Trivedi U, Blackman DJ, Levy RD, Brecker SJ, Baumbach A, Daniel T, Gray H, Mullen MJ. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol. 2011 Nov 8;58(20):2130-8. doi: 10.1016/j.jacc.2011.08.050. Epub 2011 Oct 20.</citation>
    <PMID>22019110</PMID>
  </reference>
  <reference>
    <citation>Abdel-Wahab M, Zahn R, Horack M, Gerckens U, Schuler G, Sievert H, Eggebrecht H, Senges J, Richardt G; German transcatheter aortic valve interventions registry investigators. Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German transcatheter aortic valve interventions registry. Heart. 2011 Jun;97(11):899-906. doi: 10.1136/hrt.2010.217158. Epub 2011 Mar 12.</citation>
    <PMID>21398694</PMID>
  </reference>
  <reference>
    <citation>Sherif MA, Abdel-Wahab M, Stöcker B, Geist V, Richardt D, Tölg R, Richardt G. Anatomic and procedural predictors of paravalvular aortic regurgitation after implantation of the Medtronic CoreValve bioprosthesis. J Am Coll Cardiol. 2010 Nov 9;56(20):1623-9. doi: 10.1016/j.jacc.2010.06.035.</citation>
    <PMID>21050971</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>July 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>June 18, 2017</last_update_submitted>
  <last_update_submitted_qc>June 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic stenosis</keyword>
  <keyword>TAVI</keyword>
  <keyword>Device success</keyword>
  <keyword>Aortic regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

